Novel Antibiotic Class Under Development


The Swiss Innovation Agency (Innosuisse) has granted funding jointly to a commercial entity Polyphor and the University of Zurich to develop a new class of antibiotics. The mode of action of the prototype Thanatin involves inhibition of a lipopolysaccharide transport pathway critical to maintain the outer membrane of Gram-negative bacteria. The new class referred to as Outer Membrane Protein Targeting Antibiotics (OMPTAs) is currently under evaluation to target multiple drug resistant strains of Pseudomonas aeruginosa.